Donor cells take on Drug-Resistant viruses in new trial

NCT ID NCT07670468

Recruiting now Disease control Sponsor: LucasBio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a treatment called LB-DTK-MV, which uses immune cells from a healthy donor to fight three viruses (CMV, BKV, and EBV) that have become resistant to standard antiviral drugs. The study includes 27 adults who have had a stem cell transplant or certain cancer therapies. Participants receive two infusions of these donor cells, and researchers will monitor safety, side effects, and whether the viral levels drop.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LB-DTK-MV (donor immune cells targeting multiple viruses)
What this could lead to: If successful, this could offer a new treatment option for patients with dangerous viral infections that do not respond to standard antiviral drugs after cancer therapy or stem cell transplant.
What could go wrong: This is an early-phase trial with only 27 participants, so results may not apply to everyone. There is a risk of side effects, and the treatment may not effectively clear the viruses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BKV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

BK-virus nephropathy cytomegalovirus infection Epstein-Barr virus infection Infections viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BKV INFECTION CMV INFECTION EBV INFECTION

Contacts and locations

Locations

The Catholic University of Korea Seoul St.Mary's Hospital
RECRUITING

Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.